Find Therapeutics is a clinical-stage biopharmaceutical company advancing novel therapies for demyelinating diseases such as Multiple Sclerosis and Chronic Optic Neuropathy. Its lead candidate, tasronetide (formerly FTX-101), is a first-in-class peptide that targets the NRP1/Plexin-A1 receptor complex to promote natural remyelination and neuroprotection. Preclinical studies have shown robust myelin repair, and a completed Phase I trial in healthy subjects demonstrated that tasronetide is safe and well tolerated. The company is preparing for a Phase 1b PET imaging study in MS patients and broader Phase 2-readiness activities. Find Therapeutics licenses its core technology from scientific founder Dr. Dominique Bagnard at the University of Strasbourg and is supported by investors CTI Life Sciences, Investissement Québec, and adMare BioInnovations. The recent CAD$10 million Series A extension strengthens its balance sheet to finance upcoming clinical milestones and corporate growth. Dr. Thierry Abribat, a seasoned biotech entrepreneur, has been appointed Executive Chairman to guide strategic development.

Total raised

$7M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2026